Close Menu

Amgen

Adaptive Biotechnologies will measure minimal residual disease in multiple myeloma patients as part of an Amgen-sponsored clinical trial.

The one-year partnership will focus on identifying patients with abnormal pain conditions and validating the genetic findings as potential targets for drugs.

The alliance's first aim is the identification, development, and validation of biomarkers of cancer and treatment response.

This Week in Nature

In Nature this week: paternal age associated with de novo mutations in children, and more.

An analysis of more than 1,500 Icelandic families suggests new mutations in children born to older Moms are distinct and tend to cluster in some parts of the genome.

Illumina and Amgen co-developed the test, which will determine whether metastatic colorectal cancer patients will benefit from Vectibix.

Researchers identified truncating, psychosis-related mutations in RBM12 in a family affected by schizophrenia or other psychosis disorders.

Using extensive genetic data from an Icelandic population, researchers identified two rare variants associated with osteoarthritis and related hip replacements.

Lower, But…

A trial of a drug that mimics a PCSK9 gene mutation doesn't quite meet expectations, both Nature News and Forbes say.

This Week in PLOS

In PLOS this week: mitochondrial mutation linked to tubulointerstitial kidney disease, asthma protection variant, and more.

Pages

The former commissioner of the FDA has returned to the venture capital firm New Enterprise Associates as a special partner on the healthcare investment team.

Astronauts have edited yeast genes on the International Space Station in an experiment designed to show how cells repair themselves in space.

Emory University has found that two of its researchers failed to divulge they had received funds from China, according to the Atlanta Journal-Constitution.

In Science this week: influence of the nuclear genome on human mitochondrial DNA, and more.